Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sitagliptin + Metformin Clear all

Conditions: Type2 Diabetes Mellitus
Interventions: Bexagliflozin, Metformin, Glimepiride, Sitagliptin; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Sitagliptin 100 mg, DS-8500a 25mg, Placebo Tablet, Placebo Capsule; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 48
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Tempe, Arizona + 41 more

Conditions: Obesity
Interventions: Metformin, VI-0521, Sitagliptan, Probenecid; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, placebo, sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 19
States / cities: Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, sitagliptin, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 60
States / cities: Birmingham, Alabama • Escondido, California • Fresno, California + 54 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, sitagliptin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 58
States / cities: Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 21
States / cities: Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Sitagliptin; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 51
States / cities: Peoria, Arizona • Artesia, California • Concord, California + 48 more

Conditions: Diabetes
Interventions: Sitagliptin, Metformin, Sitagliptin + Metformin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes
Interventions: SK-0403, Placebo, Sitagliptin; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 37 more

Conditions: Type 2 Diabetes Mellitus
Interventions: LCQ908A, Placebo, Sitagliptin, metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 48
States / cities: Mesa, Arizona • Little Rock, Arkansas • Buena Park, California + 39 more

Conditions: Type 2 Diabetes
Interventions: ITCA 650 60 mcg/day, sitagliptin; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Hayward, California

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, sitagliptin, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, sitagliptin, metformin, sulphonylurea; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Vestavia Hills, Alabama • Orange, California • Santa Monica, California + 7 more

Conditions: Diabetes Mellitus
Interventions: SYR-472, Placebo, Sitagliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 105
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more

Conditions: Type II Diabetes, Nonalcoholic Fatty Liver
Interventions: DPP4 inhibitor, Pioglitazone, Lantus insulin; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 45
States / cities: Huntsville, Alabama • Ozark, Alabama • Anaheim, California + 42 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Dapagliflozin, Sitagliptin, Placebo matching with Saxagliptin, Placebo matching with Dapagliflozin, Placebo matching with Sitagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 40
States / cities: Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 34 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, metformin, sitagliptin, pioglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 18
States / cities: Buena Park, California • Los Angeles, California • Valencia, California + 15 more

Conditions: Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions: Canagliflozin (JNJ-28431754), Sitagliptin, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more

Conditions: Type 2 Diabetes, Hyperlipidemia
Interventions: Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: La Mesa, California • Los Angeles, California • Los Gatos, California + 17 more

Search by objective public record fields.

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Sitagliptin in Combination With Metformin and Sulfonylurea

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM

A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Fatty Liver Study in Patients With Type II Diabetes

Dapagliflozin DPPIV Inhibitor add-on Study

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin